MedTrace Logo

Study of Biomarkers of Immune Activation Associated with Symptoms and Immune Responses After Influenza Vaccination in Adults

NCT03160118 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2024-09-19

No results posted yet for this study

Summary

This clinical fase IV study, using the administration of a single dose of a quadrivalent, inactivated, split influenza virus vaccine as biological intervention will mirror a study conducted at Imperial College, London, UK that will use a challenge with live virus as intervention. Comparison of the clinical observations and laboratory measurements generated in both studies will inform us about the similarities and differences in innate and adaptive immune responses elicited by both types of exposure to influenza virus antigen(s).

Conditions

  • Prevention of Influenza

Interventions

DRUG

Seasonal,quadrivalent,influenza vaccine

1 dose to be administered on Day 0, the first visit

Sponsors & Collaborators

  • CEVAC Core Lab, University Ghent

    collaborator UNKNOWN

  • Max Planck Institute for Infection Biology (MPIIB), Berlin, Germany

    collaborator UNKNOWN

  • deCODE genetics, Iceland

    collaborator UNKNOWN

  • VisMederi srl, Sienna, Italy

    collaborator UNKNOWN

  • University Hospital, Ghent

    lead OTHER

Principal Investigators

  • Geert Leroux-Roels, Prof., PhD · University Ghent / University Hospital Ghent

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
24 Years
Max Age
54 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-03-27
Primary Completion
2017-05-17
Completion
2017-06-28

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03160118 on ClinicalTrials.gov